Business Wire

LIVA-HEALTHCARE

4.3.2021 08:02:04 CET | Business Wire | Press release

Share
Liva Healthcare Attracts Top Medical Scientific Leaders to Global Advisory Board

A leading provider of scalable digital health coaching in Europe, Liva Healthcare (“Liva”), launches new Scientific Advisory Board. Liva has attracted some of Europe’s most respected scientific leaders within chronic conditions and behaviour change psychology to join its global Advisory Board. The board will oversee the medical quality of the programmes and conduct the latest scientific research into Liva’s behavioural change model.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005646/en/

Liva is a health tech company that improve the lives of people at risk of, or living with, chronic conditions such as type 2 diabetes, obesity, and cardiovascular diseases by driving positive behavioural change. Liva recently announced a new funding round of EUR 24.5 million with the aim to expand its European operations. The Liva programmes are used by leading players in public healthcare, insurance and life science industries globally.

Through an app, Liva provides personal human coaching programmes to help people manage their condition and develop healthier habits that last. Liva’s combination of scalable health coaching focused on personal human relationships, with an intuitive and user-friendly interface, has proven to drive substantial clinical outcomes, and is particularly effective among traditionally hard to reach socio-economic groups.

Users on the programme living with obesity have an average sustained weight loss of 6,8kg during the first 9 months, 85% of users at high risk of developing type 2 diabetes reduce their HbA1c levels in 6 months, and 44% of users living with type 2 diabetes normalise their HbA1c level and achieve ‘control’ of their condition after 12 months on the programme (HbA1c level gets below 48 mmol/mol (6,5%).

The Advisory Board will be chaired by Liva’s Chief Medical Officer, MD, PhD, Carl J. Brandt, Postdoctoral researcher at the Research Unit for General Practice, University of Southern Denmark.

“We are proud to present a global Advisory Board of this calibre. With this board, Liva has managed to attract some of Europe’s top scientific leaders to oversee the medical and ethical quality of the Liva programmes, give input on study scope and design, and oversee the evidence-based nature of the Liva programmes,” says Dr. Brandt. “We have gathered multiple competences within our therapeutic and technological areas to guide decision-making and ensure science and research is the foundation for everything we do,” adds Dr. Brandt.

Joining Liva’s Advisory Board is Prof. Dr Lisette Van Gemert-Pijnen, Chair of Persuasive Health Technology at university of Twente, and Head of Centre for eHealth & Wellbeing Research.

“In our research at university of Twente and the Centre for eHealth & Wellbeing Research, we study how persuasive health technology can be applied to increase self-management of long-term chronic diseases, like diabetes,” says Prof. Gemert-Pijnen. “Liva Healthcare has demonstrated impressive proven clinical outcomes in chronic disease prevention and management, especially within obesity, prediabetes and type 2 diabetes, and that is why I have decided to join the Advisory Board.”

“I have been conducting research on the Dutch COVID-19 contact tracing app: CoronaMelder, and COVID-19 has taught us the importance of user-friendly, reliable and inclusive digital health tools. Generally, there has been a shift in acceptance of remote healthcare, and the need for credible digital solutions is now greater than ever. Fortunately, the Liva programmes have demonstrated how effective personalised, remote health solutions can be, and I am delighted to take a seat in this highly competent Advisory Board,” adds Prof. Gemert-Pijnen.

Additional Advisory Board members include:

- Prof. Timothy Skinner, Director of University department of Rural Health at La Trobe University, and Professor of Health Psychology at University of Copenhagen. Prof. Skinner has been responsible for developing several diabetes self-management support programmes, including DESMOND, the longest standing NHS training course for people with type 2 diabetes.

- Prof. Thorsten Lewalter, Head of Department of Cardiology, int. Klinikum München Süd, and Director of Department of Cardiology, Peter Osypka Heart Center. Prof. Lewalter is a renowned cardiology expert. He is co-editor of numerous professional journals and is considered one of the founders of modern therapy of cardiac arrhythmias.

- Stephanie Kaiser, Founder and Managing Director of the digital health platform Heartbeat Labs. Kaiser has more than 12 years’ experience in building and developing digital, consumer-oriented products. Since 2018, Kaiser has been a member of the Digital Council that advises the chancellor of Germany and the German government on the important matter of digitalisation.

- Prof. Åke Sjöholm, Associate Professor of Medicine at University of Gävle, Associate Professor at Karolinska Institute, Professor of University of South Alabama, and Associate Professor Diabetes at Region Gävleborg. Prof. Sjöholm is a prominent Swedish diabetes expert and has been listed as a noteworthy diabetes researcher by Marquis Who's Who.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Swedish Court Further Reschedules Delivery of Judgment in PriceRunner Vs Google Antitrust Case24.6.2026 20:55:00 CEST | Press release

Klarna provides investor update Klarna Group plc (NYSE: KLAR) wishes to update investors that the Patent and Market Court in Stockholm, Sweden (Patent- och marknadsdomstolen) has again postponed publication of its judgment in the antitrust damages proceedings brought by PriceRunner, a Klarna subsidiary, against Google. The Court has rescheduled publication of its judgment from June 26, 2026 to July 1, 2026 at 13:00 CET. As with the Court's two previous notifications, the rescheduling is a procedural decision by the Court and relates solely to the timing of the judgment delivery. In its notification, the Court cited high workload as the reason for needing additional time to finalize the judgment. No inference about the outcome should be drawn from it. Important Notice The outcome of the proceedings is inherently uncertain. No assurance can be given that PriceRunner will succeed on liability or quantum. Any award would be subject to appeal by Google, to sharing arrangements with former P

Vertex Energy Announces 6,000 bpd Group III Base Oil Expansion Project24.6.2026 16:00:00 CEST | Press release

Vertex Energy, Inc. (“Vertex” or the “Company”) today announced it is advancing a project at its Mobile, Alabama refinery to produce crude-derived conventional Group III base oils through the Company’s existing hydrocracker and related processing infrastructure, providing lubricant manufacturers and blenders with an additional domestic source of high-quality Group III supply. The project is designed to add an incremental 6,000 barrels per day of conventional Group III production capacity and support production of 4 cSt, 6 cSt, and 8 cSt Group III base oils using an existing crude-derived hydrocracked vacuum gas oil stream produced at the Company’s Mobile, Alabama refinery. Combined with the Company’s existing re-refined Group III base oil production, this additional capacity is expected to make Vertex the leading Group III producer in North America. Vertex has completed preliminary design work and has procured a high-pressure lubricants hydrotreating unit. The Company plans to start pr

Taktile Secures $110M in Goldman Sachs-led Series C to Power AI Transformation in Financial Institutions24.6.2026 15:30:00 CEST | Press release

Growth Equity at Goldman Sachs Alternatives backs Taktile as a leading enabler of AI-driven efficiency and performance gains in banks and insurers. Taktile, the leader in AI transformation for financial institutions, today announced its $110 million Series C fundraise. Growth Equity at Goldman Sachs Alternatives led the round, with participation from Balderton Capital, Index Ventures, Tiger Global, Y Combinator, and Dig Ventures. Taktile Fast Facts Taktile enables banks and insurers to transform into AI-native organizations that are increasingly powered by autonomous agents. Demand for Taktile accelerated in 2025, as AI models became capable of automating high-stakes decisions that previously required hours of manual work—from underwriting business loans and assessing claims to catching financial crime. Customers automate and optimize decisions with Taktile by combining its financial services expertise and product built for sector-specific AI use cases. One of the world’s largest insur

New MetLife Study Reveals a 72% “Confidence Gap” in Ability to Recover from Life's Setbacks24.6.2026 15:25:00 CEST | Press release

Multinational study finds preparedness, early life experiences, and community support play a critical role in building resilience and confidence, reinforcing MetLife’s purpose. Sports, education, and mentorship at a young age shape long-term confidence and resilience. MetLife and MetLife Foundation are supporting initiatives like the FIFA Global Citizen Education Fund to expand access to education and sports programs for youth in communities worldwide, supporting their future success. A new multinational study from MetLife reveals a striking “confidence gap”: while most adults describe themselves as resilient, their confidence drops by 72% when faced with real-life setbacks. The Confident Pathways Report, conducted across the United States, United Kingdom, Japan, and Mexico, was designed to better understand how confidence is built and sustained throughout life. The findings underscore the role of opportunity, preparedness, and support in building confidence - factors that help people

StatLab Launches CytoPath Disc, Advancing Standardized Cell Block Preparation Worldwide24.6.2026 15:08:00 CEST | Press release

Simple, user-friendly product enables effective cytology cell concentration without complex steps, integrating seamlessly into existing pathology workflows. StatLab Medical Products, a leading global developer and manufacturer of pathology supplies and equipment, today announced the global launch of the CytoPath Disc, an innovative cell block preparation technology designed to standardize and simplify cell block preparation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624368623/en/ Developed as an alternative to traditional cell block methods, which convert concentrated cells suspended in fluid into a paraffin-embedded format for slide-based evaluation, the patent‑pending CytoPath Disc offers a more streamlined and efficient approach. The CytoPath Disc absorbs concentrated cells within a simple, sponge-like matrix, which is then processed, embedded, stained, and sectioned using standard histology workflows. Traditional

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye